Coca-Cola Femsa SAB de CV ADR (KOF)vsWest Pharmaceutical Services Inc (WST)
KOF
Coca-Cola Femsa SAB de CV ADR
$105.77
-0.34%
CONSUMER DEFENSIVE · Cap: $22.39B
WST
West Pharmaceutical Services Inc
$325.92
+1.21%
HEALTHCARE · Cap: $22.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Coca-Cola Femsa SAB de CV ADR generates 8981% more annual revenue ($292.51B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 7.9%. WST appears more attractively valued with a PEG of 2.89. WST earns a higher WallStSmart Score of 67/100 (B-).
KOF
Buy50
out of 100
Grade: C-
WST
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+79.7%
Fair Value
$555.46
Current Price
$105.77
$449.69 discount
Margin of Safety
-32.4%
Fair Value
$185.95
Current Price
$325.92
$139.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Generating 7.6B in free cash flow
Earnings expanding 56.1% YoY
Safe zone — low bankruptcy risk
Strong operational efficiency at 21.7%
Revenue surging 21.0% year-over-year
Areas to Watch
1.6% revenue growth
7.9% margin — thin
Weak financial health signals
Expensive relative to growth rate
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : KOF
The strongest argument for KOF centers on Price/Book, Free Cash Flow.
Bull Case : WST
The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.
Bear Case : KOF
The primary concerns for KOF are Revenue Growth, Profit Margin, Piotroski F-Score.
Bear Case : WST
The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.
Key Dynamics to Monitor
KOF profiles as a value stock while WST is a growth play — different risk/reward profiles.
WST carries more volatility with a beta of 1.17 — expect wider price swings.
WST is growing revenue faster at 21.0% — sustainability is the question.
KOF generates stronger free cash flow (7.6B), providing more financial flexibility.
Bottom Line
WST scores higher overall (67/100 vs 50/100), backed by strong 16.9% margins and 21.0% revenue growth. KOF offers better value entry with a 79.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Coca-Cola Femsa SAB de CV ADR
CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA
Coca-Cola FEMSA, SAB de CV, a franchise bottler, produces, markets, sells and distributes Coca-Cola brand beverages. The company is headquartered in Mexico City, Mexico.
Visit Website →West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other BEVERAGES - NON-ALCOHOLIC Stocks
Want to dig deeper into these stocks?